Company: GMRE
Filing Date: 2025-11-14
Form Type: 424B5
Source: 0001104659-25-112543
Chunk: 22

Company: Global Medical REIT Inc.
Filing Date: 2025-11-14
Form: 424B5
Chunk 22
---
 of such net proceeds, and you will not have the opportunity, as part of your investment
decision, to assess whether such proceeds are being used appropriately. As a result, the net proceeds from this offering may be used for
purposes that do not increase our operating results or enhance the value of our Series B Preferred Stock.

If our common stock is delisted, your ability to transfer or sell your shares of the Series B Preferred Stock may be limited and the market value of the Series B Preferred Stock will be materially adversely affected.

Other than in connection with certain Change of
Control transactions, the Series B Preferred Stock does not contain provisions that protect you if our common stock is delisted.
Since the Series B Preferred Stock has no stated maturity date, you may be forced to hold your shares of the Series B Preferred
Stock and receive stated dividends on the stock when, as and if authorized by the Board of Directors and declared by us with no assurance
as to ever receiving the liquidation preference. In addition, if our common stock is delisted, it is likely that the Series B Preferred
Stock will be delisted as well. Accordingly, if our common stock is delisted, your ability to transfer or sell your shares of the Series B
Preferred Stock may be limited and the market value of the Series A Preferred Stock will be materially adversely affected.

<div align='center'>S-12</div>

Our charter, including the Articles Supplementary designating the Series B Preferred Stock, contains restrictions upon transfer and ownership of our stock, which may impair the ability of holders to acquire the Series B Preferred Stock or convert Series B Preferred Stock into our common stock.

Our charter, including the Articles Supplementary,
contains restrictions on transfer and ownership of our stock intended to, among other purposes, assist us in maintaining our qualification
as a REIT for U.S. federal income tax purposes. Our charter provides that generally no person, other than certain exempted holders, may
own, or be deemed to own by virtue of the attribution provisions of the Code, more than 9.8% in value or in number of shares, whichever
is more restrictive, of the outstanding shares of any class or series of our stock. See “Description of the Series B Preferred
Stock — Restrictions on Transfer and Ownership” in this prospectus supplement and “Restrictions on Ownership and Transfer”
in the accompanying prospectus. You should consider these ownership limitations prior to your purchase of the Series B Preferred
Stock. No holder of Series B Preferred Stock will be entitled to